# Carfilzomib in Combination for the Treatment of RR MM

> **NCT04004338** · — · UNKNOWN · sponsor: **Black Sea Hematology Association** · enrollment: 300 (estimated)

## Conditions studied

- Multiple Myeloma
- Relapse Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Kyprolis

## Key facts

- **NCT ID:** NCT04004338
- **Lead sponsor:** Black Sea Hematology Association
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-14
- **Primary completion:** 2021-04-14
- **Final completion:** 2021-04-14
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2019-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04004338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04004338, "Carfilzomib in Combination for the Treatment of RR MM". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04004338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*